Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Identification of non-P450 enzymes involved in the metabolism of new drugs: Their significance in drug interaction evaluation and prodrug disposition.

Nishiya Y, Suzuki E, Ishizuka T, Kazui M, Sakurai H, Nakai D.

Drug Metab Pharmacokinet. 2019 Dec 24. pii: S1347-4367(19)30232-0. doi: 10.1016/j.dmpk.2019.11.001. [Epub ahead of print] Review. No abstract available.

PMID:
31926835
2.

Comparison of the Intestinal Drug Permeation and Accumulation Between Normal Human Intestinal Tissues and Human Intestinal Tissues With Ulcerative Colitis.

Nakai D, Miyake M, Hashimoto A.

J Pharm Sci. 2019 Dec 20. pii: S0022-3549(19)30823-8. doi: 10.1016/j.xphs.2019.12.015. [Epub ahead of print]

PMID:
31870787
3.

ATF7 mediates TNF-α-induced telomere shortening.

Maekawa T, Liu B, Nakai D, Yoshida K, Nakamura KI, Yasukawa M, Koike M, Takubo K, Chatton B, Ishikawa F, Masutomi K, Ishii S.

Nucleic Acids Res. 2018 May 18;46(9):4487-4504. doi: 10.1093/nar/gky155.

4.

Ecm33 is a novel factor involved in efficient glucose uptake for nutrition-responsive TORC1 signaling in yeast.

Umekawa M, Ujihara M, Nakai D, Takematsu H, Wakayama M.

FEBS Lett. 2017 Nov;591(22):3721-3729. doi: 10.1002/1873-3468.12882. Epub 2017 Oct 27.

5.

[Clinical Study on the Efficacy and Continuous Docetaxel Based Chemotherapy Treatment for Castration-Resistant Prostate Cancer].

Chikazawa I, Inoue S, Nakazawa Y, Nakai D, Morita N, Tanaka T, Motoo Y, Miyazawa K.

Hinyokika Kiyo. 2017 Sep;63(9):351-357. doi: 10.14989/ActaUrolJap_63_9_351. Japanese.

6.

Inhibitory Potency of Marketed Drugs for Ulcerative Colitis and Crohn's Disease on PEPT1.

Miyake M, Fujishima M, Nakai D.

Biol Pharm Bull. 2017;40(9):1572-1575. doi: 10.1248/bpb.b17-00181.

7.

Observation of Clinically Relevant Drug Interaction in Chimeric Mice with Humanized Livers: The Case of Valproic Acid and Carbapenem Antibiotics.

Suzuki E, Koyama K, Nakai D, Goda R, Kuga H, Chiba K.

Eur J Drug Metab Pharmacokinet. 2017 Dec;42(6):965-972. doi: 10.1007/s13318-017-0413-2.

PMID:
28447323
8.

THE EFFECT OF RADIATION THERAPY FOR BONE METASTASIS IN URINARY ORGAN CANCER.

Chikazawa I, Inoue S, Nakazawa Y, Nakai D, Ishii T, Tachibana H, Suga K, Morita N, Tanaka T, Ota K, Matoba M, Miyazawa K.

Nihon Hinyokika Gakkai Zasshi. 2016;107(1):7-12. doi: 10.5980/jpnjurol.107.7. Japanese.

9.

Effect of proinflammatory cytokine IL-6 on efflux transport of rebamipide in Caco-2 cells.

Miyake M, Nakai D.

Xenobiotica. 2017 Sep;47(9):821-824. doi: 10.1080/00498254.2016.1229085. Epub 2016 Sep 7.

PMID:
27557477
10.

The Pro-inflammatory Cytokine Interleukin-6 Regulates Nanoparticle Transport Across Model Follicle-Associated Epithelium Cells.

Miyake M, Ragnarsson E, Nakai D, Artursson P.

J Pharm Sci. 2016 Jul;105(7):2099-104. doi: 10.1016/j.xphs.2016.03.043. Epub 2016 Jun 1.

PMID:
27262206
11.

Stereoselective hydroxylation by CYP2C19 and oxidation by ADH4 in the in vitro metabolism of tivantinib.

Nishiya Y, Nakai D, Urasaki Y, Takakusa H, Ohsuki S, Iwano Y, Yasukochi T, Takayama T, Bazyo S, Oza C, Kurihara A, Savage RE, Izumi T.

Xenobiotica. 2016 Nov;46(11):967-76. doi: 10.3109/00498254.2016.1144896. Epub 2016 Feb 22.

PMID:
26899628
12.

Liver-selective distribution in rats supports the importance of active uptake into the liver via organic anion transporting polypeptides (OATPs) in humans.

Mikkaichi T, Nakai D, Yoshigae Y, Imaoka T, Okudaira N, Izumi T.

Drug Metab Pharmacokinet. 2015 Oct;30(5):334-40. doi: 10.1016/j.dmpk.2015.06.003. Epub 2015 Jun 24.

PMID:
26403085
13.

Discovery and structure-guided optimization of tert-butyl 6-(phenoxymethyl)-3-(trifluoromethyl)benzoates as liver X receptor agonists.

Matsui Y, Yamaguchi T, Yamazaki T, Yoshida M, Arai M, Terasaka N, Honzumi S, Wakabayashi K, Hayashi S, Nakai D, Hanzawa H, Tamaki K.

Bioorg Med Chem Lett. 2015 Sep 15;25(18):3914-20. doi: 10.1016/j.bmcl.2015.07.047. Epub 2015 Jul 23.

PMID:
26238323
14.

In vivo inhibition of acylpeptide hydrolase by carbapenem antibiotics causes the decrease of plasma concentration of valproic acid in dogs.

Suzuki E, Nakai D, Ikenaga H, Fusegawa K, Goda R, Kobayashi N, Kuga H, Izumi T.

Xenobiotica. 2016;46(2):126-31. doi: 10.3109/00498254.2015.1054002. Epub 2015 Jun 15.

PMID:
26075835
16.

Metabolism and disposition of [(14)C]tivantinib after oral administration to humans, dogs and rats.

Murai T, Takakusa H, Nakai D, Kamiyama E, Taira T, Kimura T, Jimbo T, Bathala M, Pickersgill F, Zahir H, Tokui T, Savage RE, Ashwell MA, Izumi T.

Xenobiotica. 2014 Nov;44(11):996-1008. doi: 10.3109/00498254.2014.926572. Epub 2014 Jun 9.

PMID:
24911380
17.

Identification of bioactivating enzymes involved in the hydrolysis of laninamivir octanoate, a long-acting neuraminidase inhibitor, in human pulmonary tissue.

Koyama K, Ogura Y, Nakai D, Watanabe M, Munemasa T, Oofune Y, Kubota K, Shinagawa A, Izumi T.

Drug Metab Dispos. 2014 Jun;42(6):1031-8. doi: 10.1124/dmd.114.057620. Epub 2014 Mar 28.

PMID:
24682756
18.

Incidence and predictors of difficult nasotracheal intubation with airway scope.

Ono K, Goto T, Nakai D, Ueki S, Takenaka S, Moriya T.

J Anesth. 2014 Oct;28(5):650-4. doi: 10.1007/s00540-013-1778-2. Epub 2014 Jan 17.

19.

Reproducibility and validity of the Japanese version of the Western Ontario Rotator Cuff Index.

Kawabata M, Miyata T, Nakai D, Sato M, Tatsuki H, Kashiwazaki Y, Saito H.

J Orthop Sci. 2013 Sep;18(5):705-11. doi: 10.1007/s00776-013-0426-x. Epub 2013 Jun 29.

PMID:
23812767
20.

Discovery and structure-activity relationship of thienopyridine derivatives as bone anabolic agents.

Saito K, Nakao A, Shinozuka T, Shimada K, Matsui S, Oizumi K, Yano K, Ohata K, Nakai D, Nagai Y, Naito S.

Bioorg Med Chem. 2013 Apr 1;21(7):1628-42. doi: 10.1016/j.bmc.2013.01.071. Epub 2013 Feb 11.

PMID:
23453217
21.

Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.

Koyama K, Nakai D, Takahashi M, Nakai N, Kobayashi N, Imai T, Izumi T.

Drug Metab Dispos. 2013 Jan;41(1):180-7. doi: 10.1124/dmd.112.048280. Epub 2012 Oct 22.

PMID:
23091189
22.

Human small intestinal and colonic tissue mounted in the Ussing chamber as a tool for characterizing the intestinal absorption of drugs.

Rozehnal V, Nakai D, Hoepner U, Fischer T, Kamiyama E, Takahashi M, Yasuda S, Mueller J.

Eur J Pharm Sci. 2012 Aug 15;46(5):367-73. doi: 10.1016/j.ejps.2012.02.025. Epub 2012 Mar 7.

PMID:
22418036
23.

Synthesis and evaluation of CS-2100, a potent, orally active and S1P(3)- sparing S1P(1) agonist.

Nakamura T, Asano M, Sekiguchi Y, Mizuno Y, Tamaki K, Nara F, Kawase Y, Yabe Y, Nakai D, Kamiyama E, Urasaki-Kaneno Y, Shimozato T, Doi-Komuro H, Kagari T, Tomisato W, Inoue R, Nagasaki M, Yuita H, Oguchi-Oshima K, Kaneko R, Nishi T.

Eur J Med Chem. 2012 May;51:92-8. doi: 10.1016/j.ejmech.2012.02.022. Epub 2012 Feb 25.

PMID:
22405291
24.

Giant cell arteritis with polymyalgia rheumatica associated with influenza vaccination.

Wada M, Asai J, Asai A, Nakai D, Kishimoto S, Katoh N.

J Dermatol. 2011 Nov;38(11):1099-101. doi: 10.1111/j.1346-8138.2011.01277.x. Epub 2011 Sep 23. No abstract available.

PMID:
21950841
25.

Inhibition mechanism of carbapenem antibiotics on acylpeptide hydrolase, a key enzyme in the interaction with valproic acid.

Suzuki E, Nakai D, Yamamura N, Kobayashi N, Okazaki O, Izumi T.

Xenobiotica. 2011 Nov;41(11):958-63. doi: 10.3109/00498254.2011.596582. Epub 2011 Jul 20.

PMID:
21770850
26.

Structural features determining the intestinal epithelial permeability and efflux of novel HIV-1 protease inhibitors.

Lazorova L, Hubatsch I, Ekegren JK, Gising J, Nakai D, Zaki NM, Bergström CA, Norinder U, Larhed M, Artursson P.

J Pharm Sci. 2011 Sep;100(9):3763-72. doi: 10.1002/jps.22570. Epub 2011 Apr 13.

27.

Identification of valproic acid glucuronide hydrolase as a key enzyme for the interaction of valproic acid with carbapenem antibiotics.

Suzuki E, Yamamura N, Ogura Y, Nakai D, Kubota K, Kobayashi N, Miura S, Okazaki O.

Drug Metab Dispos. 2010 Sep;38(9):1538-44. doi: 10.1124/dmd.110.032938. Epub 2010 Jun 15.

PMID:
20551238
28.

Microdisplacement sensor using an optically trapped microprobe based on the interference scale.

Michihata M, Hayashi T, Nakai D, Takaya Y.

Rev Sci Instrum. 2010 Jan;81(1):015107. doi: 10.1063/1.3292684.

PMID:
20113129
29.

Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes.

Kamiyama E, Nakai D, Mikkaichi T, Okudaira N, Okazaki O.

Life Sci. 2010 Jan 2;86(1-2):52-8. doi: 10.1016/j.lfs.2009.11.006. Epub 2009 Nov 13.

PMID:
19914261
30.

Social isolation stress induces ATF-7 phosphorylation and impairs silencing of the 5-HT 5B receptor gene.

Maekawa T, Kim S, Nakai D, Makino C, Takagi T, Ogura H, Yamada K, Chatton B, Ishii S.

EMBO J. 2010 Jan 6;29(1):196-208. doi: 10.1038/emboj.2009.318. Epub 2009 Nov 5.

31.

Culture period-dependent change of function and expression of ATP-binding cassette transporters in Caco-2 cells.

Kamiyama E, Sugiyama D, Nakai D, Miura S, Okazaki O.

Drug Metab Dispos. 2009 Sep;37(9):1956-62. doi: 10.1124/dmd.109.027490. Epub 2009 Jun 8.

PMID:
19505989
32.

A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding.

Nakayama S, Atsumi R, Takakusa H, Kobayashi Y, Kurihara A, Nagai Y, Nakai D, Okazaki O.

Drug Metab Dispos. 2009 Sep;37(9):1970-7. doi: 10.1124/dmd.109.027797. Epub 2009 Jun 1.

PMID:
19487250
33.

Structure-based targeting of bioactive proteins into cypovirus polyhedra and application to immobilized cytokines for mammalian cell culture.

Ijiri H, Coulibaly F, Nishimura G, Nakai D, Chiu E, Takenaka C, Ikeda K, Nakazawa H, Hamada N, Kotani E, Metcalf P, Kawamata S, Mori H.

Biomaterials. 2009 Sep;30(26):4297-308. doi: 10.1016/j.biomaterials.2009.04.046. Epub 2009 May 28.

PMID:
19477509
34.

In vivo antisense activity of ENA oligonucleotides targeting PTP1B mRNA in comparison of that of 2'-MOE-modified oligonucleotides.

Koizumi M, Takagi-Sato M, Okuyama R, Araki K, Sun W, Nakai D.

Nucleic Acids Symp Ser (Oxf). 2007;(51):111-2.

PMID:
18029611
35.

Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1.

Nakagomi-Hagihara R, Nakai D, Tokui T, Abe T, Ikeda T.

Xenobiotica. 2007 May;37(5):474-86.

PMID:
17523051
36.
37.

Direct comparison of in vivo antisense activity of ENA oligonucleotides targeting PTP1B mRNA with that of 2'-O-(2-methoxy)ethyl-modified oligonucleotides.

Koizumi M, Takagi-Sato M, Okuyama R, Araki K, Sun W, Nakai D, Tsutsumi S, Kawai K.

Oligonucleotides. 2006 Fall;16(3):253-62.

PMID:
16978088
38.

Novel non-systemic inhibitor of ileal apical Na+-dependent bile acid transporter reduces serum cholesterol levels in hamsters and monkeys.

Kitayama K, Nakai D, Kono K, van der Hoop AG, Kurata H, de Wit EC, Cohen LH, Inaba T, Kohama T.

Eur J Pharmacol. 2006 Jun 6;539(1-2):89-98. Epub 2006 Apr 7.

PMID:
16687134
39.

OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker.

Nakagomi-Hagihara R, Nakai D, Kawai K, Yoshigae Y, Tokui T, Abe T, Ikeda T.

Drug Metab Dispos. 2006 May;34(5):862-9. Epub 2006 Feb 24.

PMID:
16501004
40.

Transporter mRNA expression in a conditionally immortalized rat small intestine epithelial cell line (TR-SIE).

Hosoya K, Tomi M, Takayama M, Komokata Y, Nakai D, Tokui T, Nishimura K, Ueda M, Obinata M, Hori S, Ohtsuki S, Amidon GL, Terasaki T.

Drug Metab Pharmacokinet. 2004 Aug;19(4):264-9.

41.

coq7/clk-1 regulates mitochondrial respiration and the generation of reactive oxygen species via coenzyme Q.

Nakai D, Shimizu T, Nojiri H, Uchiyama S, Koike H, Takahashi M, Hirokawa K, Shirasawa T.

Aging Cell. 2004 Oct;3(5):273-81.

42.

Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase.

Fujino H, Nakai D, Nakagomi R, Saito M, Tokui T, Kojima J.

Arzneimittelforschung. 2004;54(7):382-8.

PMID:
15344842
43.
44.

Evaluation of the protein binding ratio of drugs by a micro-scale ultracentrifugation method.

Nakai D, Kumamoto K, Sakikawa C, Kosaka T, Tokui T.

J Pharm Sci. 2004 Apr;93(4):847-54.

PMID:
14999723
45.

Design and synthesis of oatp subtype-specific antisense oligonucleotides having 2'-O,4'-C-ethylene-bridged nucleic acids (ENA).

Takagi M, Morita K, Nakai D, Nakagomi R, Tokui T, Koizumi M.

Nucleic Acids Res Suppl. 2003;(3):83-4.

PMID:
14510391
46.

T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice.

Terasaka N, Hiroshima A, Koieyama T, Ubukata N, Morikawa Y, Nakai D, Inaba T.

FEBS Lett. 2003 Feb 11;536(1-3):6-11.

47.

Mouse homologue of coq7/clk-1, longevity gene in Caenorhabditis elegans, is essential for coenzyme Q synthesis, maintenance of mitochondrial integrity, and neurogenesis.

Nakai D, Yuasa S, Takahashi M, Shimizu T, Asaumi S, Isono K, Takao T, Suzuki Y, Kuroyanagi H, Hirokawa K, Koseki H, Shirsawa T.

Biochem Biophys Res Commun. 2001 Nov 30;289(2):463-71.

PMID:
11716496
48.

Mouse coq7/clk-1 orthologue rescued slowed rhythmic behavior and extended life span of clk-1 longevity mutant in Caenorhabditis elegans.

Takahashi M, Asaumi S, Honda S, Suzuki Y, Nakai D, Kuroyanagi H, Shimizu T, Honda Y, Shirasawa T.

Biochem Biophys Res Commun. 2001 Aug 24;286(3):534-40.

PMID:
11511092
49.

Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes.

Nakai D, Nakagomi R, Furuta Y, Tokui T, Abe T, Ikeda T, Nishimura K.

J Pharmacol Exp Ther. 2001 Jun;297(3):861-7.

PMID:
11356905
50.

Molecular identification of a rat novel organic anion transporter moat1, which transports prostaglandin D(2), leukotriene C(4), and taurocholate.

Nishio T, Adachi H, Nakagomi R, Tokui T, Sato E, Tanemoto M, Fujiwara K, Okabe M, Onogawa T, Suzuki T, Nakai D, Shiiba K, Suzuki M, Ohtani H, Kondo Y, Unno M, Ito S, Iinuma K, Nunoki K, Matsuno S, Abe T.

Biochem Biophys Res Commun. 2000 Sep 7;275(3):831-8.

PMID:
10973807

Supplemental Content

Support Center